''Iain Ross said he was extremely pleased to be able to re-join the Board of Novogen at a time when the Company is making great progress on all fronts. ''
"The management team is extremely capable and experienced and I look forward to working again in particular with Dr Andrew Heaton, who was responsible for the discovery of the super-benzopyran technology platform, Dr Justine Stehn, who along with Professor Peter Gunning are responsible for out anti-tropomyosin assets and the Company's CSO Dr David Brown," Mr Ross said.
The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University.
IMO,
The person of most interest here is professor Gil Mor - original member of CanTx Management Team along with Heaton, Brown and Kelly..
Good Luck and keep researching all the endless possibilities
- Forums
- ASX - By Stock
- Alzheimer's Disease and Tau and several other neurodegenerative diseases
''Iain Ross said he was extremely pleased to be able to re-join...
-
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add KZA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online